AZD3043 has been used in trials studying the treatment and basic science of Safety, Sedation, Tolerability, and Pharmacokinetics.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Hydrocodone | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Magnesium sulfate | The therapeutic efficacy of AZD-3043 can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | AZD-3043 may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Mirtazapine | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Orphenadrine | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Pramipexole | AZD-3043 may increase the sedative activities of Pramipexole. |
| Ropinirole | AZD-3043 may increase the sedative activities of Ropinirole. |
| Rotigotine | AZD-3043 may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with AZD-3043. |
| Suvorexant | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Thalidomide | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with AZD-3043. |
| Sodium oxybate | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ethanol | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | AZD-3043 may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Alaproclate. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with AZD-3043. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with AZD-3043. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with AZD-3043. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with AZD-3043. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with AZD-3043. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with AZD-3043. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with AZD-3043. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with AZD-3043. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with AZD-3043. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with AZD-3043. |
| Dosulepin | The risk or severity of CNS depression can be increased when Dosulepin is combined with AZD-3043. |
| Zopiclone | The risk or severity of adverse effects can be increased when AZD-3043 is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with AZD-3043. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with AZD-3043. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with AZD-3043. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of AZD-3043. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with AZD-3043. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with AZD-3043. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with AZD-3043. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with AZD-3043. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with AZD-3043. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with AZD-3043. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with AZD-3043. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with AZD-3043. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with AZD-3043. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with AZD-3043. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with AZD-3043. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with AZD-3043. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with AZD-3043. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with AZD-3043. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with AZD-3043. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with AZD-3043. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with AZD-3043. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with AZD-3043. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with AZD-3043. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with AZD-3043. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with AZD-3043. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with AZD-3043. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with AZD-3043. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with AZD-3043. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with AZD-3043. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with AZD-3043. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with AZD-3043. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with AZD-3043. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with AZD-3043. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with AZD-3043. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with AZD-3043. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with AZD-3043. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with AZD-3043. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with AZD-3043. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with AZD-3043. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with AZD-3043. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with AZD-3043. |
| Alprazolam | The risk or severity of CNS depression can be increased when Alprazolam is combined with AZD-3043. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with AZD-3043. |